🫀 GLP-1 RAs Reduce Limb Events, CV Risk, and Mortality in Diabetes with Prior Limb Events

🧪 What was studied — Nationwide retrospective cohort (Taiwan; n=17,288) of patients with diabetes and prior major adverse limb events (MALEs) comparing initiation of GLP-1 RAs (semaglutide, liraglutide, dulaglutide) vs DPP-4 inhibitors. Composite limb outcome, CV events, mortality, and progression to dialysis tracked.

📈 Key results — GLP-1 RA users had lower risks for:

• MALEs (SHR 0.90; 95% CI 0.83–0.97)
• Amputation specifically (SHR 0.86; 95% CI 0.75–0.98)
• Major adverse CV events (HR 0.62; 95% CI 0.58–0.65)
• CV death (HR 0.57), all-cause mortality (HR 0.63), and kidney replacement therapy (SHR 0.61).

📍 What this changes in practice — For diabetic patients with prior limb events, GLP-1 RAs (including semaglutide) should be prioritized over DPP-4 inhibitors for secondary CV, mortality, and limb event prevention. Consider incorporating GLP-1 RAs into care protocols for this high-risk group.

🔗 Source — PubMed | JAMA Network Open

🔥 Semaglutide: Robust, Durable Weight Loss—but Monitor for Serious AEs

🔥 Main in 3 points

• Semaglutide yields ~12.2 kg absolute and ~12.1% relative weight loss in non-diabetic adults vs. placebo.
• Benefit extends to both oral and injectable formulations.
• Serious adverse events (SAEs)—mainly GI—are higher in semaglutide groups.

🧪 Context — Meta-analysis of 7 RCTs, n=5,411, non-diabetic adults with BMI ≥27, median extended follow-up; both oral and injectable compared.

📍 Practical significance — Semaglutide is highly effective for weight management in non-diabetics, but counsel regarding GI AEs and carefully monitor for potential SAEs; pair with lifestyle interventions for maximal effect.

🔗 Source — PubMed | DOI

❓ Does Semaglutide Improve Liver Fibrosis in Noncirrhotic MASH with T2DM?

✅ Study answer — In patients with noncirrhotic MASH and T2DM, semaglutide did not significantly improve fibrosis (RR 1.21, 95% CI 0.94–1.56; p=0.13) vs. placebo, but it did improve fibrosis in non-diabetic MASH (RR 1.72, 95% CI 1.21–2.44; p=0.002). By contrast, resmetirom improved fibrosis in T2DM/MASH, but not non-diabetics.

📍 How to apply — For MASH with T2DM, clinicians should temper expectations for fibrosis regression with semaglutide; benefits may be greater in non-diabetics. Consider alternative agents (e.g., resmetirom) for diabetic patients prioritizing histologic liver improvement.

🔗 Source — PubMed | DOI

⚠️ Semaglutide: Case Report of NAION — Be Alert for Visual Loss

🧪 Context — Single reported case (Ireland): 50-year-old male on semaglutide presented with acute, painless visual loss (right eye). Diagnosed as non-arteritic anterior ischemic optic neuropathy (NAION). Drug ceased; case unique in local literature.

📊 Numbers — No quantified risk; individual case. Literature notes increasing recognition of GLP-1 RAs as possible NAION risk factors.

📍 Actions — Advise patients on semaglutide to report new visual symptoms promptly; assess for vascular risk before starting in those with predisposing factors. Increased vigilance warranted if patients present with vision changes.

🔗 Source — PubMed

🧾 Oral Semaglutide + PPI: Enhanced HbA1c Reduction—What to Do

✅ Do

• Anticipate greater HbA1c reduction over 52 weeks if a patient is co-prescribed proton pump inhibitors (PPIs) with oral semaglutide (mean HbA1c drop: -1.56% vs. -1.08%; p=0.024).

⚠️ With caution

• Monitor for AEs, though rates were similar (24.0% vs. 31.7%, NS).

🚫 Avoid

• Over-interpretation in the absence of pharmacokinetic confirmation; sample small, exploratory.

🔗 Source — PubMed | DOI

⚠️ Pancreatic Cystic Neoplasms with Semaglutide—Alert for New Lesions

🧪 Context — Two middle-aged women, no risk factors, developed large mucinous cystic neoplasms (MCN) of the pancreas after semaglutide use. Both required surgical resection; pathology confirmed MCN without malignancy.

📊 Numbers — Only two cases; temporal relationship and existing literature suggest a possible class effect (also animal studies of cystic changes with GLP-1 RAs).

📍 Actions — Maintain vigilance for pancreatic cystic lesions in patients on semaglutide, especially with new abdominal symptoms; consider imaging if clinically indicated. Causality not established—further research needed.

🔗 Source — PubMed | DOI

🫀 Semaglutide Improves Endothelial Function in T2DM

🧪 What was studied — Retrospective observational study in Japanese patients with T2DM (n=24) beginning once-weekly semaglutide. Primary outcome: reactive hyperemia index (vascular endothelial function).

📈 Key results — Significant improvement in RHI (pre: 1.62±0.19, post: 2.04±0.60; p<0.01), body weight, HbA1c, LDL cholesterol also improved. No correlation between changes in clinical markers and RHI.

📍 What this changes in practice — Supports cardiovascular protective effects of semaglutide; semaglutide not only improves glycemic and lipid metrics, but may also confer direct vascular benefits.

🔗 Source — PubMed | DOI

✅ Semaglutide for Pretransplant Weight Loss: Case-Based Safety

🧪 What was studied — Case report: Obese liver transplant candidate (BMI 39.1), oral semaglutide pre-op, 10 kg loss in 19 days → improved graft-to-recipient weight ratio, successful transplantation, no complications.

📍 How to apply — Consider short-term semaglutide for weight reduction in obese liver transplant candidates where preoperative weight loss is crucial. Monitor closely perioperatively; more data needed on this approach.

🔗 Source — PubMed | DOI

🔥 Semaglutide in PAD: Now Endorsed for CV Protection

🔥 Main in 3 points

• NEJM update: Recommends semaglutide as part of foundational therapy for peripheral artery disease alongside statins, anti-platelets, BP control, SGLT2is.
• Supported by latest CV and kidney outcomes data.
• Exercise and revascularization still key for functional and refractory cases, respectively.

🧪 Context — Expert review/guideline in NEJM, broad population impact.

📍 Practical significance — Where available, offer semaglutide for PAD patients (especially those with T2DM and/or high CV risk), as part of a comprehensive prevention plan.

🔗 Source — PubMed | DOI

⚠️ GI, Renal, and Pancreatic Safety Signals—Semaglutide & Class Review

🧪 Context — Disproportionality (FAERS) analysis: Semaglutide most associated with GI adverse event signals (PRR 3.97, ROR 14.21); liraglutide strongest for renal/pancreatic events; semaglutide notable for diabetic ketoacidosis (PRR 5.86, ROR 5.9) and AKI.

📍 Actions — GI events with semaglutide are expected; stay alert for rare DKA and AKI, especially in at-risk patients (e.g., dehydration, renal compromise). Surveillance limitations apply; clinical vigilance still warranted.

🔗 Source — PubMed | DOI

🧠 GLP-1 RAs and Psychiatric Effects: Mostly Stable, Minor New-Onset Risk

🧪 What was studied — Retrospective EHR review of 226 adults (mean age 53.5, 73% semaglutide) on GLP-1 RAs, high psychiatric comorbidity rates.

📈 Key results — MDD and GAD stable in ~75% of patients. New-onset MDD in 9%, GAD in 8.7%, with ~16 months’ latency. Some rare new alcohol/opioid use disorders.

📍 What this changes in practice — GLP-1 RAs (esp. semaglutide) are generally psychiatrically well tolerated, though high-risk patients may rarely develop or exacerbate symptoms; ensure proactive monitoring and patient education.

🔗 Source — PubMed | DOI

⬇️ Semaglutide Shifts Food Preferences—Underlying Mechanism for Weight Loss

🧪 What was studied — Retrospective observational study; 32 Japanese T2DM patients (20 started semaglutide, 12 controls); dietary assessments at 6 months.

📈 Key results — Semaglutide led to significant reductions in body weight, HbA1c, and preference for sweet/non-sweet carbohydrates and fats (not protein/fiber). No preference change seen in controls.

📍 What this means — Semaglutide supports weight loss by actively reducing patient cravings for high-carb and high-fat foods. Discuss anticipated dietary changes and monitor for adequacy of nutrition.

🔗 Source — PubMed | DOI